KURA Form 144: 8,891 RSU Shares Proposed Sale on 09/29/2025

Kura Oncology (KURA) Form 144 notice states that an individual proposes to sell 8,891 shares of common stock on or about 09/29/2025 through Morgan Stanley Smith Barney LLC on NASDAQ.

Rhea-AI Filing Summary

Kura Oncology (KURA) Form 144 notice states that an individual proposes to sell 8,891 shares of common stock on or about 09/29/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports an aggregate market value of $80,463.55 and total shares outstanding of 87,015,518. The shares were acquired as RSUs from the issuer on 09/27/2025 and are listed as payable on 09/29/2025. The filer reports no sales of the issuer's securities in the past three months and includes the standard signature representation that no undisclosed material adverse information is known.

Insights

Securities Analyst

TL;DR: Insider sale is small relative to outstanding shares and market capitalization, indicating limited market impact.

The proposed sale of 8,891 shares valued at $80,463.55 represents a de minimis portion of Kura Oncology's 87,015,518 outstanding shares. The sale follows RSU acquisition on 09/27/2025, suggesting a routine post-vesting disposition rather than a large liquidation. No other sales in the past three months were reported, reducing likelihood of a pattern of insider selling. For investors, this filing is procedural and not materially informative about company fundamentals.

Corporate Governance Expert

TL;DR: Filing complies with Rule 144 disclosure; transaction appears routine and includes required attestation.

The notice discloses the broker, proposed sale date, and acquisition details (RSU on 09/27/2025) consistent with Rule 144 requirements. The absence of prior three-month sales and the inclusion of the standard representation regarding material non-public information indicate adherence to disclosure norms. There is no indication of procedural issues or governance irregularities from the information provided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KURA's Form 144 disclose about the proposed sale?

The notice discloses a proposed sale of 8,891 common shares on 09/29/2025 via Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $80,463.55.

How were the shares being sold acquired?

The shares were acquired as RSUs from the issuer on 09/27/2025 and are listed for sale with payment date 09/29/2025.

Did the filer report any other sales in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker is handling the proposed sale?

The broker named in the filing is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY.

How large is the proposed sale relative to outstanding shares?

The proposed sale of 8,891 shares compares to 87,015,518 shares outstanding, representing a negligible percentage of the share count.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/29/2025 - 07:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001934232
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KURA ONCOLOGY, INC.
SEC File Number	001-37620
Address of Issuer	12730 High Bluff Drive San Diego CALIFORNIA 92130
Phone	(858)-500-8800
Name of Person for Whose Account the Securities are To Be Sold	POWL BRIAN T
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8891	80463.55	87015518	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/27/2025	RSU	Issuer			8891	09/29/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Thomas Doyle, Attorney-in-fact for Brian Powl
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)